When voters across the U.S. cast their ballots in Tuesday’s elections, they will not just be deciding who will control [...] …
Blog Posts
A major group purchasing organization (GPO) is suing the federal government over a policy that it claims unlawfully restricts how [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The 340B program continues to be a central topic of discussion in the pharmaceutical landscape, especially as specialty medications become an increasing portion of healthcare spending. Specialty pharmacies, covered entities (CEs), and manufacturers are navigating a complex environment shaped by regulatory updates, financial
…
Eli Lilly is backing Sanofi’s lawsuit to compel the federal government to release all 340B contract pharmacy agreements, arguing that [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmaker Boehringer Ingelheim (BI) will begin requiring all 340B covered entities to submit claims data to continue accessing 340B drugs [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices. [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Biden Administration has asked a federal appeals court to reconsider a Texas judge’s ruling that voided a Department of [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pfizer’s top executive told investors this week that the 340B program “is one of the biggest issues,” during an earnings [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmakers Xellia Pharmaceuticals and Ascend Laboratories will refund 340B providers for some products following ceiling price recalculations, according to notices [...] …